Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC3110A (QIV) in Healthy Children
NCT02541253Phase 3Completed
- Sponsor
- GC Biopharma
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GC Flu Quadrivalent in influenza (2 arms), sponsored by GC Biopharma. Primary endpoints: Percentage of participants achieving seroconversion for HI antibody at Day 28 and Percentage of participants achieving seroprotection for HI antibody at Day 28. Started Sep 2015; status: completed.
02
Drugs
GC Flu Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02541253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541253.